DexCom sees Q4 revenue at least $815M, consensus $807.65M

DexCom reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31 to be at least $815M, an increase of 17% over the fourth quarter of 2021 on a reported basis and 20% on an organic basis. U.S. revenue is expected to be approximately $606M, representing growth of 17% over the fourth quarter of 2021. International revenue is expected to be approximately $209M, an increase of 15% over the fourth quarter of 2021 on a reported basis and 26% on an organic asis. For fiscal 2022, total preliminary, unaudited revenue is expected to be approximately $2.91 billion, an increase of 19% over 2021 on both a reported and organic basis.